Form 4: C4 Therapeutics Director Increases Stake Through Stock Compensation
Insider Transaction Report
Donna Roy Grogan, a Director at C4 Therapeutics, Inc., acquired 9,609 shares of common stock on July 1, 2025, as part of her non-employee director compensation, increasing her total beneficial ownership to 51,889 shares.
Summary
- Donna Roy Grogan, a Director of C4 Therapeutics, Inc. (CCCC), acquired 9,609 shares of common stock.
- The acquisition occurred on July 1, 2025, at a price of $1.51 per share, based on the closing market price.
- These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy.
- Grogan elected to receive common stock instead of cash compensation for her services as a non-employee director.
- Following this transaction, Donna Roy Grogan beneficially owns 51,889 shares of C4 Therapeutics, Inc. common stock.
Sentiment
Score: 7
Explanation: The acquisition of shares by a director in lieu of cash compensation is generally viewed positively as it indicates confidence in the company's future and aligns the director's interests with shareholders. However, the transaction size is relatively small in the broader context of the company's equity.
Positives
- A director choosing to receive stock instead of cash compensation can signal confidence in the company's future prospects.
- Increases insider ownership, potentially aligning management interests with shareholders.
Future Outlook
No specific future outlook or guidance is provided in this Form 4.
Industry Context
This Form 4 details a routine insider transaction related to director compensation and does not provide broader industry context.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Compensation Policy Application | Application of the Issuer's Non-Employee Director Compensation Policy, allowing directors to elect shares in lieu of cash. | 07/01/2025 | Enhances alignment of director interests with shareholders by increasing equity ownership. |
Related Party Transactions
- Acquisition of 9,609 shares of common stock by Director Donna Roy Grogan from C4 Therapeutics, Inc. as compensation for services, in lieu of cash.
Stakeholder Impact
- Shareholders: Increased insider ownership may be seen as a positive signal of confidence.
Key Dates
| Date | Description |
|---|---|
| 07/01/2025 | Date of transaction where Donna Roy Grogan acquired common stock. |
| 07/02/2025 | Date the Form 4 was signed by the attorney-in-fact for Donna Roy Grogan. |
Recommendation
holdKeywords
C4 Therapeutics, CCCC, Form 4, Insider Trading, Director Compensation, Stock Compensation, Equity Acquisition, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.